ReciBioPharm vs Wacker Biotech: CDMO Comparison
How does ReciBioPharm compare to Wacker Biotech?
As of May 2026, ReciBioPharm: no FDA inspections on file, 3 EMA/MHRA GMP certificates. Signal Score 82.9. Wacker Biotech: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 13 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of ReciBioPharm and Wacker Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Wacker Biotech has FDA inspections on record (1); ReciBioPharm does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Wacker Biotech holds 13 active EMA GMP certificates; ReciBioPharm does not appear in EudraGMDP.
- ReciBioPharm maintains 3 MHRA / UK GMP certificates; Wacker Biotech does not.
Across the cross-modality scorecard, ReciBioPharm carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: ReciBioPharm vs Wacker Biotech
How does ReciBioPharm compare to Wacker Biotech?
On CDMO Signal's composite Signal Score, ReciBioPharm is 83/100 and Wacker Biotech is 83/100; ReciBioPharm has 0 FDA inspections on record vs 1 for Wacker Biotech; European coverage is 3 active EMA+MHRA certificates for ReciBioPharm vs 13 for Wacker Biotech. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, ReciBioPharm or Wacker Biotech?
Both ReciBioPharm and Wacker Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. ReciBioPharm has 0 FDA inspections on record; Wacker Biotech has 1.
How do ReciBioPharm and Wacker Biotech compare on European GMP coverage?
ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Wacker Biotech holds 13 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
ReciBioPharm carries a Signal Score of 83/100 and Wacker Biotech carries 83/100 — essentially tied for Wacker Biotech. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →